PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems. “Given LATITUDE’s successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts,” commented PhytoMedical, President, CEO, Greg Wujek. “The development and subsequent testing of the IV Formulation are key components in PhytoMedical’s quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.”
